{
    "clinical_study": {
        "@rank": "148132", 
        "acronym": "IPI-145-14", 
        "arm_group": [
            {
                "arm_group_label": "Mild Hepatic Impairment", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Moderate Hepatic Impairment", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Healthy Subjects", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Severe Hepatic Impairment", 
                "arm_group_type": "Experimental", 
                "description": "Optional arm based on results from Arms 1, 2, and 3"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the pharmacokinetics, safety, and tolerability of IPI-145  when administered to\n      subjects with chronic hepatic impairment and in matched healthy subjects."
        }, 
        "brief_title": "IPI-145 in Hepatically Impaired Subjects Compared to Healthy Subjects", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatic Impairment", 
        "condition_browse": {
            "mesh_term": "Liver Diseases"
        }, 
        "detailed_description": {
            "textblock": "This is a nonrandomized, open-label, parallel-group, single oral dose study in subjects with\n      chronic hepatic impairment and matched (age, sex, weight, BMI) healthy subjects.  Subjects\n      will be enrolled into 1 of 3 groups based on hepatic impairment grade: mild, moderate and\n      normal hepatic function.  An optional severe hepatic impairment group will enroll based on\n      data from the mild and moderate hepatic impairment groups in comparison to matched healthy\n      group.  All subjects will receive a single oral dose of IPI-145 25 mg."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men or women of nonchildbearing potential between 18-70 years of age\n\n          -  Body Mass Index (BMI): 18.0 - 38.0 kg/m2.\n\n          -  Healthy subjects: in good health, determined by no clinically significant findings\n             from clinical evaluations\n\n          -  Hepatic impairment subjects: confirmed hepatic impairment >1 year with etiology of\n             chronic alcoholism, chronic viral hepatitis (B or C), nonalcoholic steatohepatitis,\n             autoimmune hepatitis, Wilson disease, alpha-1 antitrypsin deficiency, glycogen\n             storage diseases, or galactosemia\n\n          -  Provided written informed consent prior to any study specific procedures\n\n        Exclusion Criteria:\n\n          -  Women of childbearing potential\n\n          -  Hepatic impairment subjects: fluctuating or rapidly deteriorating hepatic function,\n             acute hepatitis, variceal bleeding within 8 weeks of screening, a history of\n             pancreatitis within 8 weeks of screening, evidence of hepatic encephalopathy > Grade\n             1, current unstable hematologic condition, and/or creatinine clearance < 60 mL/min\n\n          -  Healthy subjects: positive screening test for hepatitis B surface antigen, or\n             hepatitis C antibody\n\n          -  ECG at screening or Day -1 showing QTcF \u2265 450 msec for healthy subjects or > 500 msec\n             for hepatically impaired subjects\n\n          -  Evidence of clinically significant medical conditions\n\n          -  History of gastrointestinal disease or surgery that may affect drug absorption\n\n          -  Positive or indeterminate QuantiFERON-TB Gold test at screening\n\n          -  Any active infection at the time of screening or admission"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02095587", 
            "org_study_id": "IPI-145-14"
        }, 
        "intervention": {
            "arm_group_label": [
                "Mild Hepatic Impairment", 
                "Moderate Hepatic Impairment", 
                "Healthy Subjects", 
                "Severe Hepatic Impairment"
            ], 
            "description": "25 mg single oral capsule", 
            "intervention_name": "IPI-145", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Phase 1", 
            "hepatic impairment"
        ], 
        "lastchanged_date": "March 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Miami", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33014"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 1, Open-Label, Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of IPI-145 in Subjects With Chronic Hepatic Impairment Compared to Healthy Subjects", 
        "overall_contact": {
            "email": "Musa.Mutyaba@infi.com", 
            "last_name": "Musa Mutyaba", 
            "phone": "617-453-1426"
        }, 
        "overall_contact_backup": {
            "email": "Jylle.Nevejans@infi.com", 
            "last_name": "Jylle Nevejans", 
            "phone": "617-453-1320"
        }, 
        "overall_official": {
            "affiliation": "Clinical Pharmacology of Miami", 
            "last_name": "Dr. Kenneth Lasseter", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "PK parameters (AUC, Cmax and t1/2) of IPI-145 and its metabolite, IPI-656 Plasma concentrations of IPI-145 and its metabolite, IPI-656", 
            "measure": "Pharmacokinetic parameters of IPI-145 and its primary metabolite, IPI-656", 
            "safety_issue": "No", 
            "time_frame": "Open 72 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02095587"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Safety Findings", 
            "measure": "Incidence of adverse events following administration of IPI-145", 
            "safety_issue": "No", 
            "time_frame": "10 days"
        }, 
        "source": "Infinity Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Infinity Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}